Meetings - The ASCO Post

This is Part 3 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable...

breast cancer

/ Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer

HR-Positive/HER2-Negative Metastatic Breast Cancer With PIK3CA Mutation

This is Part 2 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable...

breast cancer

/ Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer

Second-Line Treatment of HR-Positive/HER2-Negative ESR1-Mutated Metastatic Breast Cancer

This is Part 1 of Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable...

Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer

Endocrine-Resistant HR-Positive/HER2-Negative Metastatic Breast Cancer

HR-Positive/HER2-Negative Metastatic Breast Cancer With PIK3CA Mutation

Second-Line Treatment of HR-Positive/HER2-Negative ESR1-Mutated Metastatic Breast Cancer

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being